Long-term multilineage allochimerism can be obtained in H2-mismatched B6.SJL to BALB/c transplants with host irradiation of 100 cGy, donor spleen cell pre-exposure and costimulator blockade with anti-CD40 ligand (CD40L) antibody. We evaluated this allochimerism approach in murine marrow transplants with different degrees of major histocompatibility complexe (MHC) mismatching; these include: (1) H2-mismatched transplant H2Kk to H2Kb, (2) full haplo-identical transplant H2Kbd to H2Kbk, (3) a partial haplo-identical transplant H2Kd to H2Kbd and (4) an MHC class II mismatch. Levels of chimerism increased up to 12 weeks and then stayed relatively stable up to 1 year after transplant. At 18 weeks post-transplant, the H2-mismatched, haplo-identical, partial haplo-identical and class II-mismatch transplants evidenced 17.974.4, 40.770.9, 25.174.19 and 33.773.5% donor chimerism, respectively. Dropping the anti-CD40 antibody treatment and spleen cells or changing the schedule of antibody to one injection, in haploidentical or full-mismatched transplants resulted in no donorderived chimerism. On the other hand, these still resulted in minor chimerism in class II-mismatched transplants. Lineage analysis of peripheral blood at 6 and 12 months post-transplant demonstrated a significant shift toward increased chimeric lymphocytes and decreased chimeric granulocytes in the full H2 as compared with haplo-identical or class II transplants. Transplantation with anti-CD40L antibody eliminated both graftversus-leukemia and graft-versus-host disease (GVHD) and delayed lymphocyte infusion did not rescue animals from fatal leukemia. In conclusion, under the conditions of our tolerization regimen, a haplo transplant gives higher engraftment levels than a full H2 mismatch, and despite lower engraftment levels, a class II-mismatched transplant can be successfully accomplished with only 100 cGy and no CD40L blockade.
Introduction
Minimally ablative regimens for bone marrow transplantation have recently gained significant popularity. These regimens are based on new data that suggest full myeloablation, either with radiation or with chemotherapy agents, are not needed to achieve a high level of chimerism. [1] [2] [3] [4] [5] It has been shown that in a syngeneic model, levels of engraftment of differentiated hematopoietic cells depend on the ratio of donor stem cells to recipient stem cells. 6 This does not hold completely in an allogeneic setting where interactions of donor and recipient are critically important. Major histocompatibility complexes (MHC) class I and II molecules identity is a predominant determinant of the outcome of allogeneic transplantation. Full mismatches of MHC compared to haplotypeidentical transplantations need higher levels of myeloablations to achieve the same levels of chimerism. Induction of tolerance between host and donor immune system could overcome this problem and may have an important role in the establishment of a long-lasting partial chimerism without any host-versus-graft or graft-versus-host reactions. [2] [3] [4] Our group 5 and others 7, 8 have previously shown that lowdose radiation (100 cGy) is very toxic to hematopoietic stem cells. In a syngeneic model (male to female BALB/c), we showed that by imparting 100 cGy of gamma radiation, we could achieve a level of chimerism up to 90%. In H2-mismatched allogeneic transplantation 100 cGy of radiation resulted in only minimal (less than 1%) and transient chimerism. Therefore, we looked at other approaches to induce tolerance in an allogeneic setting.
One of the most effective ways to introduce a foreign antigen (eg MHC antigen) to the host immune system (mainly to T cells) is through antigen-presenting cells (APC). Antigen needs to be processed first by the APC and then be presented to the T cells via their receptors in conjunction with the host class I or II MHC molecules. Once the appropriate signal is presented to the T cells, they start to proliferate and become either active cytotoxic effector T cells or more dormant memory cells. One of the key elements here is the presence of appropriate costimulatory signals. Costimulatory molecules are a rapidly growing class of surface molecules and many are yet to be defined.
CD40, a member of TNFR superfamily, is one of the costimulatory molecules. 9 It is expressed on B cells, dendritic cells and activated monocytes. Its ligand, CD154, belongs to the TNF family and is transiently expressed on activated T cells, mast cells and basophils. CD40 ligand (CD40L) by triggering CD40 on APC increases their cytokine production (especially interleukin-12) and upregulates expression of adhesion and other costimulatory molecules. These interactions promote the appropriate proliferative response of the T cells and induce an immune response to the antigen. [9] [10] [11] In vitro studies have shown that inhibition of CD40-CD40L interaction in an APC-T-cell reaction not only eliminated the cytotoxic effect of the T cell, but also prevented the T cells' response in a second challenge with the same antigen. 12 Anti-CD40L monoclonal antibody (mAb) was found to block acute and chronic graft-versus-host disease (GVHD) and to decrease alloreactive CD4+ thoracic duct lymphocytes. 13, 14 Wekerle et al 15 reported on costimulator blockade in mice using a combination of anti-CD40L antibody and CTLA4Ig with 300 cGy total body irradiation (TBI) and infused with hematopoietic marrow cells. They showed longterm donor-derived chimerism in fully mismatched transplants. Other groups also have shown the effectiveness of CD40-CD40L interaction blockade in the induction of tolerance for both hematopoietic 16, 17 and nonhematopoietic tissues.
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We have previously evaluated transplant models of H2-mismatched marrow using the following approach With the above protocol, we were able to achieve long-term chimerism in a full class I-mismatched transplantation model of B6.SJL to BALB/c (H2Kd to H2Kb). Skin grafts from donor B6 mice after this protocol showed engraftment without evidence of rejection, while third-party grafts were rejected. 22 In the present studies, we have extended the use of our transplantation protocol with costimulation inhibition to different MHC-mismatch models, including full class I mismatch, different haplotype mismatches and class II mismatch ( Figure 2) .
One of the main applications of bone marrow transplantation is for the treatment of leukemias and lymphomas. In allogeneic transplantation, an important aspect involves graft-versusleukemia (GVL) effects. Previous data suggest that immunosuppressive effects of the anti-CD40L antibody may not be antigen specific and its administration may adversely affect bacterial and tumoral immunity. 23 To test the effect(s) of transplantation with costimulation blockade on GVL, we used a commonly used GVL model, 24 and compared GVL and GVHD in conventional myeloablative bone marrow transplantation with our anti-CD40L nonmyeloablative protocol.
Material and methods

Animals
B10BR (H2Kk), B6.CH2 bm12 , C57BL/6 (H2Kb, CD45.2), B6SJL (H2Kb, CD45.1), (B6 Â CBA)F1 (H2Kbk), (B6 Â DBA/2)F1 (H2Kbd) were all purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were certified to be pathogen free, housed in our animal facility and given ad libitum access to food and acid water. The animals were maintained in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of Massachusetts Medical School and Roger Williams Medical Center and recommendations in the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) .
Murine anti-CD40L mAb production and quantification
The MR-1 hybridoma cell line (gift from Dr Randolph Noelle, Dartmouth Medical School, Dartmouth, NH, USA) produces murine anti-CD40L mAb. The isotype of this antibody is Armenian hamster IgG, group 3. Briefly, BALB/c SCID mice (Jackson Laboratory) were primed with 0.5 ml Pristane (2,6,10.14-tetramethylpentadecane; Sigma Chemical, St Louis, MO, USA) intraperitoneally (i.p.). At 7-10 days after the Pristane priming, 2 Â 10 6 MR-1 cells (viability 475%) were injected i.p. into each of the BALB/c SCID mice. Ascites was apparent by 7-10 days after cell injection and was then drained with sterile needles every other day. Freshly collected ascites was incubated at 371C for 1 h, then 41C overnight. After centrifugation at 3000 rpm for 30 min, supernatant was filtered through a 0.2 mm filter. Samples were aliquoted and stored at 801C. These were thawed immediately before injection into mice.
Enzyme-linked immunosorbent assay (ELISA) was used to quantitate the amount of Armenian hamster IgG in the ascites. The ELISA plates (Becton Dickinson, CA, USA) were coated with 100 ml capture antibody (affinity purified goat anti-Armenian hamster IgG) and incubated at 41C overnight. Unknown concentration ascites and commercial anti-CD40L antibody (Pharmingen, San Diego, CA, USA) were added to appropriate wells after serial dilution for 41C overnight. Biotinylated goat antihamster IgG was added to the wells followed by avidinhorseradish peroxidase at appropriate dilutions. TMB Peroxidase EIA Substrate Kit (Bio-Rad, Hercules, CA, USA) was used for detection and plates read at 650 nm. Standard curves were made from the commercial anti-CD40L antibody preparation and unknown ascites concentrations calculated based on the standard curves.
Bone marrow transplantation
The groups of transplanted animals based on their MHC characteristics include ( . In the first set of experiments, we compared class I-mismatched with haplo-and partial haplomismatched transplants. In the second set of experiments, we compared class I-and haplo-mismatched transplants to class IImismatched transplants. Six-to 8-week old male mice were used as donors or recipients. After killing the mice and dissecting the femur, tibia and pelvic bones, bone marrow were obtained by flushing the bones with HBSS with 2% heatinactivated fetal calf serum (HI-FCS) using a syringe and 25-gauge needle. After resuspension in HBSS without FCS, cells ) spleen cells were injected intravenously prior to bone marrow transplantation. Anti-CD40L antibody was injected i.p. at days -10, -7, -3, 0 and +3. At day 0, recipient mouse received 100 cGy of radiation, followed by injection of 40 million bone marrow cells. Costimulator inhibition in different transplants mismatches M Abedi et al were passed through a 40 mm cell strainer. Cell numbers were counted in crystal violet and viability was assessed by trypan blue staining. Approximately 4 h after radiation, 40 million bone marrow nucleated cells in 0.5 ml of phosphate-buffered saline (PBS) were injected intravenously by the tail vein into each recipient. A cesium gamma source was used for radiation of animals before transplantation. Mice were exposed to 100 cGy whole-body irradiation (85 cGy/min).
Donor-specific tolerance
Spleen cells were prepared by squeezing the spleen between frosted sides of two slides and suspending the cells in HBSS followed by passing them through a cell strainer. At 10 days before transplantation, 10 Â 10 6 spleen cells from donor in each group were injected to the corresponding recipient by tail vein injection. Also at day -10 and every 3rd day after, anti-CD40L antibody was injected i.p. A total of five doses of anti-CD40L (1.6 mg each) was injected i.p. into each mouse ( Figure 1 ).
GVL model
We used a previously well-established model for GVL ( Figure 3 ). In this model, C57BL/6 male donors were used as donors and (B6 Â DBA/2)F1 as recipient. The control recipients received lethal radiation (12 Gy. cesium gamma source) followed by 20 million bone marrow nucleated cells from donors. The test group received our CD40L protocol as was described above. L1210 leukemia cell line was purchased from American Type Culture Collection (ATCC). This is a T lymphocyte leukemia that has spontaneously arisen in DBA/2 (H2Kd) mice. It was MAP tested and cleared by Charles River Laboratories for the following pathogens: SEND, PVM, MHV, MVM, GD-7, REO-3, LCMV, ECTR, POLY, MAD, EDIM, LDV. Leukemia cells were cultured in Fisher's medium (Sigma) containing 10% horse serum and were incubated in 5% CO 2 . At day +7 after transplantation, 1 Â 10 5 leukemia cells were washed and resuspended in HBSS and were injected by the tail vein into the mice. At the first signs of illness (e.g. weight loss or mass), mice were killed and were screened for evidence of masses or hepatosplenomegaly. In parallel groups, leukemia cells were injected at day 50. Spleen cells were used as a source for donor lymphocyte infusion (DLI). Spleen cells from donor mice were prepared as described above and mice were given DLI, 2 days after injection of leukemia cells (day +52).
Flow cytometry
Peripheral blood was obtained from each mouse either by eye bleeding from the retro-orbital plexus under halothane anesthesia or by tail bleeding. Total peripheral donor chimerism was assessed by staining with FITC-conjugated H2-specific (H2Kd, H2Kk) antibodies. For class II-mismatch transplants anti-CD45L Ab was used. Primary antibodies were added to 50 ml of blood and samples were incubated at room temperature for 30 min. Samples were incubated for 10 min at room temperature with 1.3 ml ice-cold erythrocyte-lysing solution (150 mM NH 4 Cl, 10 mM NaHCO 3 , 1 mM EDTA, pH 7.4), washed with PBS and resuspended in PBS and 1% paraformaldehyde (Sigma, St Louis, MO, USA) and kept at 41 until analysis. Percent of donor cells was determined by calculating the percent of FITC-positive cells after correcting for background. Lineage was determined by adding lineage-specific antibodies to primary antibodies. Lineage-specific antibodies include GR-1, B220 and CD3 for neutrophils, B lymphocytes and T cells, respectively. Subtypes of T cells were further analyzed by CD4 or CD8 antibodies. Both GR-1 and B220 antibodies were PE conjugated. CD3, CD4 and CD8 antibodies were biotin labeled and streptavidin-APC was used as a secondary label. All the antibodies were purchased from Pharmingen (San Diego, CA, USA).
Progenitor assays -high proliferative potential colonyforming cell and colony-forming unit culture Cultured cells under both conditions were assessed for in vitro colony-forming unit culture (CFU-c) and high proliferative potential colony-forming cell (HPP-CFC) assay using a doublelayer soft-agar nutrient medium technique in 35 mm plastic culture dishes (Falcon). The bottom layer consisted of: 1.0 ml underlay of 0.5% agar (Difco, Detroit, MI, USA) with a-MEM (Life Technologies/Gibco/BRL), 20% FCS (Hyclone), 1% penicillin/streptomycin (Life Technologies/Gibco/BRL) and 1% L-glutamine (Life Technologies/Gibco/BRL) and seven separate growth factors. These growth factors were: recombinant murine (rm) colony-stimulating factor-1 (CSF-1) 7500 U per plate (R&D Systems, Minneapolis, MN, USA), murine granulocyte-macrophage colony-stimulating factor (GM-CSF) 3.75 ng per plate (R&D), murine IL-1 alpha 375 U per plate (R&D), rm IL-3 150 U per plate (Collaborative Research, Bedford, MA, USA), rm steel factor 150 ng per plate (R&D), murine G-CSF 7.5 ng per plate (R&D), and rm basic fibroblast growth factor 7.5 ng per plate (Collaborative). Cells were plated at a concentration of 20 000 cells per plate for the starting population and after various times in culture, a culture volume equivalent of the starting volume which contained 20 000 cells was plated in a 0.5 ml overlayer of 0.3% agar in a-MEM with 20% HI-FCS. Five culture dishes were set up per group per time point. The plates were incubated in a humidified 5% O 2 , 10% CO 2 , 85% N 2 371C water-jacketed incubator (Forma Scientific Inc., Marietta, OH, USA). After 2 weeks, the colonies were scored using a dissecting microscope at 20 Â magnification. Dishes were scored for HPP-CFC and CFU-c. HPP-CFC were considered highly dense colonies over 0.5 mm in diameter or moderately dense colonies of over 
Figure 3
Early and late leukemia relapse models for evaluation of GVL. Experiments were designed based on two clinical scenarios for recurrence of leukemia after bone marrow transplantation. In the early relapse model, animals received either 1200 cGy (myeloablative), or 100 cGy of radiation (nonmyeloablative) with CD40L, while in the late model they underwent our CD40L protocol followed by infusion of leukemia cells and donor lymphocytes at days 50 and 52, respectively.
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Statistics
We used the nonparametric Wilcoxon's rank-sum test for comparison, and the trend test developed by Cuzick for testing trend (Cuzick, 1985) . The level of significance is set at 0.05 (two sided). Data are presented as mean71 S.E. of the mean. 25 
Results
Effect of anti-CD40L antibody on bone marrow stem cells
To study the effects of anti-CD40L antibody on bone marrow stem cells, we carried out HPP assays of whole bone marrow in the presence and absence of the anti-CD40L Ab and the results showed no difference between the two groups ( Figure 4 ).
Transplantation of bone marrow cells from B10BR mice to the C57BL/6 mice (full H2 mismatch) B10BR mice are congenic mice with C57BL/6 background. The major difference between the two is the MHC class I molecule H2K. B10BR phenotype is H2Kk vs H2Kb for C57BL/6. This is a full mismatch for class I and depending on the conditioning protocol, transplantation can lead to either a significant rejection and/or a lethal GVHD. Transplantation of 40 Â 10 6 bone marrow cells from B10BR mice to untreated C57BL/6 mice did not result in meaningful chimerism of peripheral blood cells at 3, 6 or 12 weeks. When transplantation was carried out after 100 cGy, there was still no chimerism. When we used our standard protocol with pre-exposure of the host to donor splenic cells and i.p. injection of anti-CD40L, we saw 5.470.3% chimerism at 3 weeks. Chimerism increased to 16.670.9% at 6 week and to 18.973.1% at 12 weeks. Chimerism plateaued at 18 weeks (17.974.4%). At 52 weeks 13.773.4% peripheral blood chimerism was detected (Figure 5a ). No evidence of GVHD (diarrhea, changes in fur, posture or weight loss) was observed. This is lower than the level of chimerism in our previous full class I-mismatch (B6 to BALB/c) transplantation experiments. (Figure 5b ). No evidence of GVHD was observed. We also looked at a different model of haplotype mismatch, which consisted of transplantation of bone marrow from C57BL/6 mice (H2Kd) to (B6 Â DBA/2)F1 mice (H2Kbd). Since this is a partial haplo mismatch, we expected higher levels of chimerism compared to our haplo-mismatched transplanted, but surprisingly, the levels of chimerism were closer to our full class I mismatch. (Figure 5d) . Interestingly, only 100 cGy radiation followed by bone marrow cell transfusion without any other treatment in this group resulted in 3.170.4% chimerism at 3 weeks (Figure 9b ). Low-level chimerism was still present although decreased to 0.970.2% at 18 weeks even at 52 weeks post transplant 0.270.02% of the cells were still of donor origin (data not shown).
Analysis of lineage chimerism
Using double staining for chimeric cells and lineage markers, we determined the lineage-specific chimerism in each transplantation cohort. With this method, we noticed significant differences between different genetic disparities. In class I-mismatch transplants, 84% of B220 positive B lymphocytes were from donor origin, while only 2% of GR-1-positive neutrophils were from donors. In haplotype mismatch and in class II mismatch, the lineage distribution was 11 and 15% of the neutrophils from donor origin, respectively. The percentages of chimeric B lymphocytes were 69 and 35 in the latter two groups. There were less chimeric CD3-positive T cells in class Imismatched transplantations compared with haplo-or class IImismatched transplantations (14 vs 17 vs 22%, respectively) ( Figures 6 and 7) . Analysis of T-cell subpopulations showed that in class I-mismatched transplants, most of the engrafted T cells had CD4 markers, while CD8 cell engraftment was significantly higher in haplo-and class II-mismatched transplants. Also the CD8/CD4 ratio was significantly different in H2-mismatch vs haplo-or class II-mismatched transplantations (P-values of 0.032 and 0.021, respectively) The CD8/CD4 ratio differences between class II-and haplotype-mismatched transplants were not statistically significant (Figures 8 and 9 ).
Comparison of one vs five injections of CD40L antibody
To study the importance of schedule of CD40L injection in our protocol, we used either one or five injections of CD40L Lineage chimerism: relative lineage distribution. The distribution of different cell types in the donor-derived cells of peripheral blood was determined among chimeric peripheral blood cells (at 18 weeks) using GR1 (neutrophils), B220 (B cells) and CD3 (T cells). The difference was accounted for others (monocytes, eosinophils and basophils, etc). A major change in the relative distribution of neutrophils and B lymphocytes was noted with increasing genetic diversity. Full H2 mismatch had mainly chimeric lymphocytes, while class II had a more diverse distribution of different lineages including others among chimeric cells. The difference between total white blood cell counts between the groups was not statistically significant. Each bar represents five mice7s.e. Analysis at 18 weeks demonstrated similar results.
Costimulator inhibition in different transplants mismatches M Abedi et al antibody with spleen cell injection. In contrast to the five injections, one injection of CD40L antibody did not result in any meaningful chimerism in full H2-or haplotype-mismatched transplantations. On the other hand in class II mismatches, one injection of anti-CD40L antibody was enough to induce a level of chimerism close to five injections at 3 weeks (19.471.4 vs 22.671.5%, respectively) ( Figure 9 ).
GVL studies
For our leukemia models, we used L1210 leukemia cell lines. Because of its genetic background, upon infusion, these cells can grow and cause a fatal leukemia in DBA/2 or B6DF1 mice, but they fail to cause any leukemia in B6 mouse. Our preliminary data showed that intravenous injection of 10 5 L1210 leukemia cells to the (B6 Â DBA/2)F1 mice induced hepatosplenomegaly and/or visible masses within 2-3 week and animals die of leukemia around 1 month after injection (data not shown). In a well-studied model, 26 it was shown that transplantation of bone marrow cells, with or without donor lymphocytes, after lethal levels of radiation, would rescue the animals from leukemia. Design of this experiment is shown in Figure 3 . We first confirmed the evidence of GVL effect after transplantation. All mice that received leukemia cells showed evidence of disease at 3-4 weeks. On the other hand, none of the mice that received leukemia cells after bone marrow transplantation with a fully ablative regimen showed any evidence of leukemia even after 4 months. A control group that received anti-CD40L with leukemia cells but without transplantation did slightly worse than all other groups (animals developed lethal leukemia in 2675 days for anti-CD40L injection alone vs 3074 days for the control group and 3976 days for anti-CD40L bone marrow transplantation protocol, N ¼ 5 for each group). The group that underwent our standard minimally ablative regimen with the CD40L did slightly better than control, but still all the animals died within 45 days after infusion. In two parallel groups, we evaluated the infusion of DLI as a measure to rescue the animals, 50 days after bone marrow transplantation with anti-CD40L antibody protocol. Leukemia cells were injected at day 50. After 2 days, one group received DLI. All the animals in both groups developed lethal leukemia. So DLI neither prevented nor delayed the development of leukemia. When we looked at the chimerism, at 3 weeks all animals in the full myeloablative group had 100% chimerism, while the level of chimerism was 17.470.02% in mice that received our CD40L Ab protocol. Chimerism levels increased to 21 and 25% at 8 and 18 weeks, respectively. Figure 11 summarizes these data. DLI did not convert the partial chimerism to full chimerism in this model (data not shown). We also evaluated the GVHD in these experiments. A total of 100% of mice that received the myeloablative regimen for transplantation showed signs of GVHD (stooped posturing, weight loss, diarrhea and fur changes). No evidence of GVHD was observed in groups that were transplanted with costimulation inhibition. These data strongly suggest that our transplantation protocol can inhibit both GVL and GVHD reactions. These results are summarized in Figure 10 .
Discussion
We have shown that there is an increase in allochimerism from H2-mismatched to haplo-to class II-mismatched 
Figure 10
Effects of CD40L transplantation protocol on GVL. The top diagram shows peripheral blood chimerism in parallel control groups at 4 weeks. In the early relapse model, leukemia cells were administered intravenously at day +7 after transplant and in the delayed relapse model at day 50 followed by intravenous injection of 20 million spleen cells (DLI) at day 52. Animals were evaluated for signs of GVHD and for evidence of leukemia. Tables show outcomes of the experiments. Note that myeloablative bone marrow transplantation completely prevented leukemia growth, while CD40L protocol transplantation and CD40L Ab injection alone did not. Each group represents five animals. In two groups, one animal died in each group due to procedure (eg halothane anesthesia) or the reason of death was not identified. Those animals were withdrawn from analysis. To compare the two experiments in one chart, the engraftment level of the haplo mismatch, which was repeated in both experiments, was used for comparison and set as 100%. The relative difference is presented. Significant differences (Pp0.01) were found between all groups (N ¼ 10 for H2 and haplo mismatch, N ¼ 5 for partial and class II).
transplantation. Our transplantation protocol is based on presensitization with donor spleen cells and concomitant CD40/CD40L costimulator blockade for induction of the chimerism. In this work, we applied our protocol in different MHC-mismatched transplantations and compared the results. As with our previous data, we have shown that even in the haplotype-mismatch transplantations, 100 cGy of radiation are not enough, and we still need presensitization and costimulation inhibition with anti-CD40L to achieve chimerism. In our different allogeneic models radiosensitivity of different strains may have a role in the difference of allochimerism, but in all four models the recipients were either B6 or the F1 from B6 parents with very close radiosensitivy. Moreover, 100 cGy of radiation alone in none of these animals resulted in any significant chimerism. As was expected, we saw a higher level of engraftment and peripheral chimerism in the haplo-identical vs full-mismatch transplantations. Interestingly, transplantation of bone marrow cells with a partial haplotype mismatch resulted in chimerism levels that where closer to full-mismatch transplantations than our haplo-identical model (Figure 11 ). This was surprising since we expected to see better engraftment results with haplo transplantation, since F1 recipients should not reject their parent marrow cells. On the other hand, based on the other studies, this is a commonly used model for evaluating GVHD, GVL and graft rejection, and relatively high doses of radiation are needed to achieve full chimerism. This demonstrates that the kinetics of alloreactivity in such a model is still not well understood.
Working on these models has given us a better insight into the application of minimal ablation regimens in different MHC mismatch transplantations. In separate work, we have shown that chimerism can be obtained without irradiation when a relatively large number of cells (total of 200 Â 10 6 cells) are given over an intermittent schedule with cell infusion at 0, 3, 4, 5 and 6 weeks. These data were obtained in H2-mismatch transplants. 27 The application of this approach with or without CD40L blockade will be of significant interest.
There is a difference between lineage chimerism in different transplantation regimens. For example, after lethal radiation all three lineages are present while after our low-dose radiation protocol differentiation is skewed toward more B-cell chimerism and less granulocytes or T cells. 28 In our experiments, we concluded that not only the preparatory regimens but also the degree of genetic disparity determines the lineage chimerism. In full class I mismatch, there was very little chimerism in granulocytes and CD8 T cells. This was in contrast to the results of class II and haplo transplants, where chimeric lineage distribution was less skewed. The relative increase in number of CD8 compared with CD4 T cells in class II, and especially in the haplo mismatch, may be due to an increase in the population of regulatory cells that help with the maintenance of the chimerism status.
For a better understanding of the clinical applications of the above model, we also looked at the effects of our protocol on the GVL effect. First, we noticed that injection of anti-CD40L decreased the body defense against leukemia and that disease progressed faster in mice that received the antibody. Furthermore, in contrast to the fully ablative protocol, our anti-CD40L protocol resulted in little, if any, GVL effect and the induced partial chimerism did not rescue the mice from leukemia progression. Whether this is due to the tolerizing effect of partial chimerism on GVL or due to direct inhibitory effects of anti-CD40L on GVL is not clear. DLI in partial chimeric mice was previously shown to have significant GVL effects. DLI did not have any antileukemia effect in our system. This may be due to the presence of CD40L antibody at the time of DLI, since the antibody can induce a tolerance status between donor lymphocytes and the leukemia cells.
Also of interest was the effect of DLI on chimerism itself. Markus YM et al (Blood 2000; 96: 176a; abstract) showed that DLI after 30 days post bone marrow transplantation would improve chimerism. The theory behind this is induction of severe GVH reaction, which specifically affects host lymphohematopoietic cells while sparing already transplanted donor cells. Meanwhile, the host has become tolerant to the donor lymphocyte cells (because of mixed chimerism) and cannot mount a response against them. DLI did not have any effects in chimerism in our animals and in fact in one group 2 out of five animals lost their chimerism after DLI (data not shown).
Based on these data, we suggest that we can achieve high degrees of stable mixed chimerism, especially in class II or haplo-identical bone marrow transplantations, with minimal toxicities and no evidence of GVHD. At this point, we cannot justify using this protocol for treating hematological or solid tumors, since we have not observed any GVL effects. On the other hand our protocol, because of lack of GVHD and minimal toxicity of preparatory regimen, can have direct immediate applications in the treatment of diseases such as hereditary hemoglobinopathies (eg sickle cells or thalassemia) 29, 30 or for induction of tolerance for transplantation of solid organs.
